Pharmaceutical-Technology.com
VerifiedMagazine
Pharmaceutical-technology.com is one of a network of 30+ proprietary B2B websites, with an unrivalled global audience of active decision makers, influencers, and opinion leaders across the world with a combined readership of 55 million industry professionals each year.
As part of GlobalData, we have access to over 1bn data points including companies, deals, projects and forecasts and trends. Leading data informs and support our industry leading content. With expertise spanning more than 80 markets globally and driven by 800+ award-winning journalists, researchers, and analysts, we connect you with the information that makes and breaks businesses every day.
Combined with our award-winning targeting technology built into our network of websites, we offer a unique end-to-end marketing solution combining insight, creativity, and cutting-edge AI-technology. Our marketing solution allows clients to identify, target and engage with prospects using access and ownership of our 30+ B2B media websites and their large sector specific audiences. With more reach, data targeting and first-party data than any other partner, we produce world-class campaigns for our clients. For more details on our technology-driven marketing solution visit https://www.verdictmediastrategies.com/ Source
Actions
Media Outlet details
| Scope | International, Trade/B2B |
|---|---|
| Language | English |
| Country | United Kingdom |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
| Frequency | Monthly |
Recent Articles
Search ArticlesThe definitive infrastructure for modern drug development
Credit: via Shutterstock. Paradigm Health delivers a unified, AI-powered clinical research platform embedded within a national network of community and academic sites. By grounding protocol design, patient identification, and study data capture in real-world patient population insights and care delivery, we enable faster enrollment, higher-quality data, and more efficient trial execution, making studies easier to run and expanding access to clinical trials for more patients, everywhere.
Advancing pressure protection in biopharma: how integrated bypass technology elevates single-use pump design
In Association with Xylem There is no excerpt because this is a protected post. April 14, 2026 This content is password protected. To view it please enter your password below: Password:
Telix and Regeneron to co-develop radiopharmaceutical therapies Original
The partnership reflects a focus on precision oncology, seeking to enhance patient selection and assess treatment responses. The collaboration will include several solid tumour targets from Regeneron’s antibody portfolio. Credit: lev radin / Shutterstock.com. Telix and Regeneron Pharmaceuticals have entered a partnership for the development and commercialisation of new radiopharmaceutical therapies.
FDA issues complete response letter to Replimune’s RP1 for melanoma Original
Replimune’s RP1 is based on a genetically engineered herpes simplex virus intended to stimulate an anti-tumour immune response. During the IGNYTE trial, patients treated with RP1 plus nivolumab showed a 34% response rate. Credit: Evgeniy Kalinovskiy / Shutterstock.com. The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Replimune Group’s biologics licence application (BLA) concerning the RP1 therapy in combination with nivolumab for advanced melanoma.
Vetter Pharma Aseptic Manufacturing Facility, Saarland, Germany
The facility’s construction plan was formally announced by Vetter Pharma in January 2026. Credit: Vetter Pharma International GmbH. Vetter Pharma’s new aseptic manufacturing facility will be developed on a 95-acre industrial property in Saarland, Germany. Credit: Vetter Pharma International GmbH. The facility’s construction plan was formally announced by Vetter Pharma in January 2026. Credit: Vetter Pharma International GmbH.
Emerging therapies bring hope for frail HNSCC patients unfit for standard treatment Original
Standard of care HNSCC regimens with curative intent demand surgery, radiation, and chemotherapy - treatments that many patients cannot tolerate. NBTXR3 appears to be the best-positioned drug out of the three for a broad global impact as it requires no specialist laser or neutron accelerator, relying instead on existing radiotherapy infrastructure. Credit: VesnaArt via Shutterstock.com.
Sartorius Cell Culture Technology Centre, Germany
The Ulm facility earned DGNB Gold certification in August 2021. Credit: Sartorius. Sartorius’ cell culture technology centre in Ulm, Germany, was developed with an investment of €30m ($35.2m). Credit: Sartorius AG. The cell culture technology centre was opened in November 2021. Credit: Sartorius. The facility enables Sartorius to expand its Cellca CHO Expression Platform offerings. Credit: Sartorius. The Ulm facility earned DGNB Gold certification in August 2021. Credit: Sartorius.
Moderna mRNA Vaccine Manufacturing Facility, Quebec, Canada
The Laval facility produced the first doses of Moderna's Covid-19 vaccine in September 2025. Credit: Moderna, Inc. Moderna’s Laval facility can produce up to 100 million mRNA respiratory vaccine doses a year. Credit: CNW Group/Moderna, Inc. Construction of the mRNA manufacturing facility in Laval, Canada, was completed in February 2024. Credit: EXP. The Laval facility produced the first doses of Moderna's Covid-19 vaccine in September 2025. Credit: Moderna, Inc.
L.B. Bohle Hosts Successful Continuous Manufacturing Workshop in Brazil
Focus on continuous wet granulation and drying for research, development, and small-scale production The workshop on twin-screw granulation and truly continuous drying with QbCon® featured hands-on demonstrations, in-depth technical presentations and an intensive exchange of expertise. L.B. Bohle looks back on a successful workshop in Brazil. The event centred on the topic ‘Truly Continuous Wet Granulation and Drying for R&D and Small-Scale Production via Revolutionary QbCon®’.
In the face of tariffs, FDA-approved drug manufacturing deals are shifting to Europe Original
In 2025, biopharma companies increasingly invested in Europe-based contract manufacturing for FDA-approved drugs compared to US-based providers, despite US import tariffs on pharmaceuticals. The shift of CM deals for FDA-approved drugs toward Europe highlights the limited impact that European import tariffs have had to sway biopharma companies away from European-based CM and towards the US. Credit: speedshutter Photography via Shutterstock.com.